

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 02-792)

In application of:)	TER 1
	John, et al.)	Examiner: D. Luktor
Serial No.	09/594,978)	Group Art Unit: 1653
Filed:	June 15, 2000)	Group Art Omt. 1033
For:	Dipeptide Inhibitors of β-Secretase)	
		,	

COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir,

As required by 37 CFR §1.821-1.825, the computer readable form is identical in content to the written sequence listing, attached herewith, and does not go beyond the scope of the specification as filed.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Dated: 10/d1/0 L

By:

Steven J. Sarussi

Reg. No. 32,784

McDonnell, Boehnen, Hulbert & Berghoff 300 S. Wacker Drive, Suite 3200 Chicago, IL 60606 312-913-0001



SEQUENCE LISTING

<110>

Varghese, John Tung, Jay Hom, Roy Guinn, Ashley Fang, Lawrence Gailunas, Andrea Mamo, Shumeye S.

<120> Dipeptide Inhibitors of B-Secretase

<130> 02-792

<140> 09/594,978 <141> 2000-06-15

<150> 60/139,190 <151> 1999-06-15

<150> 60/173,354 <151> 1999-12-26

<160>

<170> PatentIn version 3.1

<210> 1

<211>

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic Peptide

<220>

<221> MISC_FEATURE

<222>

(1)..(1)
Xaa is 3,5-difluoroPhe/Sta <223>

<400> 1

Xaa Val Ala Glu Phe

<210> 2

<211> <212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 2

Val Ala Glu Phe

1

<210>

<211> 5

<212> PRT

Artificial Sequnce <213>

<220> <223>

synthetic peptide

<220>

<221> MISC_FEATURE

<222>

(1)..(1)
Xaa is Sta (Statine) <223>

<400> 3

Xaa Val Ala Glu Phe

RECEIVED & TOOL OF THE PROPERTY OF THE PROPERT

RECEIVED
NOV 0 4 2002
TECH CENTER 1600/2900